NCT01701115

Brief Summary

The purpose of this study is to determine if a decrease in the standard volume of local anesthetic used to numb your shoulder area before shoulder arthroscopy will provide adequate anesthesia for the procedure and decrease the amount of time until you are ready for discharge from the hospital.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
154

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Aug 2012

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2012

Completed
2 months until next milestone

First Submitted

Initial submission to the registry

September 24, 2012

Completed
10 days until next milestone

First Posted

Study publicly available on registry

October 4, 2012

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2013

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2013

Completed
4.2 years until next milestone

Results Posted

Study results publicly available

October 4, 2017

Completed
Last Updated

October 4, 2017

Status Verified

October 1, 2017

Enrollment Period

1 year

First QC Date

September 24, 2012

Results QC Date

April 3, 2017

Last Update Submit

October 2, 2017

Conditions

Keywords

Interscalene Block

Outcome Measures

Primary Outcomes (1)

  • Handgrip Strength

    The primary outcome will be handgrip strength as measured by a dynamometer. A reading will be obtained at baseline (before the interscalene block) and 60 minutes post-operative.

    Difference between between baseline and postoperative.

Secondary Outcomes (3)

  • Patient Readiness to Discharge

    Participants will be followed every 15 minutes post-surgery until discharged from the hospital (up to 180 minutes)

  • Duration of Analgesia

    Postoperative Day 2

  • Side Effects

    Postoperative Day 2

Study Arms (2)

Low Dose (20 mL) Local Anesthetic

EXPERIMENTAL

Intervention to be administered is a total volume of 20 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine.

Procedure: Low Dose (20 ml) Local Anesthetic Volume for Interscalene BlockDrug: Low Dose (20 mL) Local Anesthetic (Mepivacaine:Bupivacaine)

Control Dose (40 mL) Local Anesthetic

ACTIVE COMPARATOR

Intervention to be administered is a total volume of 40 mL local anesthetic containing a 1:1 mixture of 1.5% Mepivacaine: 0.5% Bupivacaine

Procedure: Control Dose (40 mL) Local Anesthetic Volume for Interscalene BlockDrug: Control Dose (40 mL) Local Anesthetic (Mepivacaine:Bupivacaine)

Interventions

Anesthetic volume: Investigational group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 20 mL

Low Dose (20 mL) Local Anesthetic

Anesthetic volume: Control group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 40 mL

Control Dose (40 mL) Local Anesthetic
Also known as: Mepivacaine, Bupivacaine
Low Dose (20 mL) Local Anesthetic
Also known as: Mepivacaine, Bupivacaine
Control Dose (40 mL) Local Anesthetic

Eligibility Criteria

Age18 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age: 18 - 80 years old
  • Surgical time \< 2.5 hours
  • ASA I, II or III
  • Shoulder arthroscopy

You may not qualify if:

  • Age \< 18 or \> 80 years old
  • Chronic pain patients (on narcotics/opioids \> 3 months)
  • Open shoulder surgical procedure
  • BMI \> 40
  • Pre-existing neurological condition
  • Patient refusal of interscalene block
  • Severe respiratory disease or hemidiaphragmatic dysfunction
  • Allergy to any local anesthetics
  • Planned general anesthesia

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hospital for Special Surgery

New York, New York, 10021, United States

Location

MeSH Terms

Interventions

Anesthetics, LocalMepivacaineBupivacaine

Intervention Hierarchy (Ancestors)

AnestheticsCentral Nervous System DepressantsPhysiological Effects of DrugsPharmacologic ActionsChemical Actions and UsesSensory System AgentsPeripheral Nervous System AgentsCentral Nervous System AgentsTherapeutic UsesPiperidinesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsAnilidesAmidesOrganic ChemicalsAniline CompoundsAmines

Results Point of Contact

Title
Dr. Daniel Maalouf
Organization
HSS

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 24, 2012

First Posted

October 4, 2012

Study Start

August 1, 2012

Primary Completion

August 1, 2013

Study Completion

August 1, 2013

Last Updated

October 4, 2017

Results First Posted

October 4, 2017

Record last verified: 2017-10

Locations